CN101248061A - 厄贝沙坦碱土金属盐水合物及其制备 - Google Patents

厄贝沙坦碱土金属盐水合物及其制备 Download PDF

Info

Publication number
CN101248061A
CN101248061A CNA2006800198798A CN200680019879A CN101248061A CN 101248061 A CN101248061 A CN 101248061A CN A2006800198798 A CNA2006800198798 A CN A2006800198798A CN 200680019879 A CN200680019879 A CN 200680019879A CN 101248061 A CN101248061 A CN 101248061A
Authority
CN
China
Prior art keywords
irbesartan
salt
alkaline
preparation
tetrahydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2006800198798A
Other languages
English (en)
Other versions
CN101248061B (zh
Inventor
A·阿洛姆巴德
P·默塞伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101248061A publication Critical patent/CN101248061A/zh
Application granted granted Critical
Publication of CN101248061B publication Critical patent/CN101248061B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明的目的是在药学上可接受的厄贝沙坦碱土金属盐水合物及其在含水介质中的制备。

Description

厄贝沙坦碱土金属盐水合物及其制备
本发明的目的是厄贝沙坦(irbesartan)碱土金属盐水合物及其制备。
厄贝沙坦是血管紧张素II AT1受体的拮抗剂，其作为抗高血压的和治疗糖尿病的肾病的药进行销售的。
在专利EP 454 511 B中公开的厄贝沙坦，它的化学名是2-正-丁基-3-[(2′-(1H-四唑-5-基)联苯-4-基)]甲基]-1，3-二氮杂螺[4，4]壬-1-烯-4-酮，其式如下：
Figure S2006800198798D00011
在这个专利中，列举了与有机或无机碱生成的盐，例如与碱金属或碱土金属生成的盐，以及特别描述了在一些有机溶剂中制备厄贝沙坦钾盐。
在美国专利US 6 162 922及其等同的欧洲专利EP 1 060 165 B提到厄贝沙坦与无机酸生成的盐，即溴酸盐、盐酸盐和硫酸盐。
专利EP 708 103 B描述了厄贝沙坦的2种互变异构形式：形式A和形式B。这个专利指出，形式A呈不吸湿的稳定针形，具有高静电性。而且，专利EP 1089 994还描述了厄贝沙坦形式A的新晶体惯态；在这个专利中，提到具有针状惯态的厄贝沙坦形式A的晶体难以过滤与干燥，其流动性也不好。
现在发现采用一种方法可以很容易得到在药学上可接受的厄贝沙坦碱土金属盐水合物，该方法的步骤是在含水溶液中进行的。它涉及厄贝沙坦钙盐和镁盐水合物，更特别地厄贝沙坦钙盐四水合物和厄贝沙坦镁盐四水合物。
因此，本发明的目的是在药学上可接受的厄贝沙坦碱土金属盐的水合物，即厄贝沙坦钙盐和镁盐；本发明特别涉及厄贝沙坦钙盐四水合物和厄贝沙坦镁盐四水合物，更特别地涉及这些化合物的结晶形式。
本发明的盐是采用一种方法制备的，该方法特征在于：
-在含水溶液中制备厄贝沙坦钠盐；然后
-在含水介质中用期望的碱土金属盐置换厄贝沙坦钠盐。
如此生成的厄贝沙坦碱土金属盐水合物采用过滤进行分离；然后进行干燥。
因此，本发明方法的2个步骤是在含水介质中进行的，这样有许多优点：
-没有残留溶剂，因此降低成本，和没有环境问题；
-在该方法的2个步骤中可以对这些水溶液进行灭菌；
-可控生成盐结晶；
-所得到盐容易过滤与干燥；
-所得到盐无静电性与易于压制。
记录了厄贝沙坦钙盐四水合物和厄贝沙坦镁盐四水合物结晶形式的粉末X射线衍射图(RX)。粉末X射线衍射图(衍射角)是在下述条件下测定的：使用Bragg-Brentano型，Philips X′pert(θ/θ)衍射仪；源CuKα1、
Figure S2006800198798D00021
扫描范围2°-40°，在Bragg2θ中每分钟1°。
观察到，厄贝沙坦钙盐四水合物和厄贝沙坦镁盐四水合物的粉末衍射曲线图是几乎相同的。
2种化合物的粉末衍射图的特征射线列于下表中：
  峰   角
  埃   2-θ°
  12.62765   7
  9.30946   9.5
  8.50577   10.4
  7.08112   12.5
  6.41684   13.8
  6.32562   14
  5.64430   15.7
  5.53914   16
  4.82170   18.4
  4.72000   18.8
由它们的粉末衍射图测定了每种盐的晶格参数。
厄贝沙坦镁盐四水合物。
Figure S2006800198798D00031
晶格体积：
Figure S2006800198798D00032
Figure S2006800198798D00033
表示埃
厄贝沙坦钙盐四水合物。
Figure S2006800198798D00034
晶格体积：
Figure S2006800198798D00035
这些晶格参数的观测值的大约值是与2种化合物的粉末衍射图的相似性是一致的。
因此，本发明另一个目的是结晶形式的厄贝沙坦钙盐或镁盐四水合物。
在下面的实施例中，高效液相色谱采用了下述的高效液相色谱英语缩写HPLC。
实施例1
厄贝沙坦钙盐四水合物。
将42.8g厄贝沙坦溶于由4g氢氧化钠与430ml水制备的溶液中。把这种溶液倒入由11.1g氯化钙与500ml水制备的溶液中。如此得到的反应介质在50℃加热4小时，然后让其返回到室温。得到的盐进行过滤，用100ml水漂洗3次，然后在50℃真空下干燥直到恒重。得到47.1g期望的盐。
采用HPLC测定产物纯度为99.6％。
RMN(核磁共振)谱分析表明没有相应于四唑质子的峰，所述的峰在未成盐的厄贝沙坦的RMN谱中是存在的。
百分比分析得到下述结果：
Figure S2006800198798D00041
采用HPLC测定的在厄贝沙坦盐中的厄贝沙坦含量是81.34％(理论值：82.26％)。
采用离子HPLC测定的钙含量是3.86％(理论值：3.90％)。
电位测定表明，2次跳跃相等于40.83％和39.04％，这些跳跃相应于期望理论值(总值82.26％)。
这种电位测定能够通过用高氯酸测定对所述盐的2个碱性官能进行定量，而定量在厄贝沙坦盐中存在的厄贝沙坦量。
采用Kad Fisher法(15.4％,即4H2O)和采用热重法测定了所得到盐的水含量：该热重法能够测定在100℃的质量损失，即以质量计水损失：12.96％，即每摩尔产物为4摩尔水。
对所得盐记录的RX粉末衍射图列于图1。
实施例2
厄贝沙坦镁盐四水合物。
将42.8g厄贝沙坦溶于由4g氢氧化钠与430ml水制备的溶液中。把这种溶液倒入由9.52g氯化镁与500ml水制备的溶液中。如此得到的反应介质在50℃加热4小时，然后让其返回到室温。得到的盐进行过滤，用100ml水漂洗3次，然后在50℃真空下干燥直到恒重。得到47.5g期望的盐。
采用HPLC测定产物纯度为99.6％。
RMN(核磁共振)谱分析表明没有相应于四唑质子的峰。
百分比分析得到下述结果：
Figure S2006800198798D00043
Figure S2006800198798D00051
采用HPLC测定的该盐中厄贝沙坦含量是82.39％(理论值：83.50％)。
采用离子HPLC测定的镁含量是2.35％(理论值：2.87％)。
电位测定表明，2次跳跃相等于41.29％和88.12％。
采用Karl Fisher法测定所得到盐的水含量(15.86％，即4H2O)和采用热重法测定所得到盐的水含量：12.26％，即每摩尔产物为4摩尔水。
对所得盐的记录的RX粉末衍射图列于图2。

Claims (6)

1.在药学上可接受的厄贝沙坦碱土金属盐水合物。
2.根据权利要求1所述的厄贝沙坦盐水合物，它选自厄贝沙坦钙盐水合物和镁盐水合物。
3.厄贝沙坦钙盐四水合物。
4.厄贝沙坦镁盐四水合物。
5.结晶形式的厄贝沙坦钙盐和镁盐四水合物。
6.根据权利要求1-5中任一项权利要求所述的厄贝沙坦盐水合物的制备方法，其特征在于：
-在含水溶液中制备厄贝沙坦钠盐；然后
-在含水介质中用期望的碱土金属盐置换厄贝沙坦钠盐。
CN2006800198798A 2005-06-06 2006-06-06 厄贝沙坦碱土金属盐水合物及其制备 Expired - Fee Related CN101248061B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0505755 2005-06-06
FR0505755A FR2886642B1 (fr) 2005-06-06 2005-06-06 Sels alcalino-terreux d'irbesartan et leur preparation
PCT/FR2006/001267 WO2006131632A1 (fr) 2005-06-06 2006-06-06 Hydrates de sels alcalino-terreux d'irbesartan et leur preparation

Publications (2)

Publication Number Publication Date
CN101248061A true CN101248061A (zh) 2008-08-20
CN101248061B CN101248061B (zh) 2011-08-24

Family

ID=35639476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800198798A Expired - Fee Related CN101248061B (zh) 2005-06-06 2006-06-06 厄贝沙坦碱土金属盐水合物及其制备

Country Status (17)

Country Link
US (1) US7947842B2 (zh)
EP (1) EP1891054A1 (zh)
JP (1) JP2008542435A (zh)
KR (1) KR20080024473A (zh)
CN (1) CN101248061B (zh)
AR (1) AR054131A1 (zh)
AU (1) AU2006256678A1 (zh)
BR (1) BRPI0610933A2 (zh)
CA (1) CA2610665A1 (zh)
FR (1) FR2886642B1 (zh)
HK (1) HK1123793A1 (zh)
IL (1) IL187723A (zh)
MX (1) MX2007015426A (zh)
RU (1) RU2401266C2 (zh)
TW (1) TW200716099A (zh)
UY (1) UY29584A1 (zh)
WO (1) WO2006131632A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111175385A (zh) * 2018-11-12 2020-05-19 珠海润都制药股份有限公司 一种厄贝沙坦中厄贝沙坦同分异构体检验方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
AR032758A1 (es) * 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
CN1548421A (zh) * 2003-05-22 2004-11-24 上海医药工业研究院 替米沙坦盐及其制备方法
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111175385A (zh) * 2018-11-12 2020-05-19 珠海润都制药股份有限公司 一种厄贝沙坦中厄贝沙坦同分异构体检验方法

Also Published As

Publication number Publication date
IL187723A (en) 2011-06-30
US7947842B2 (en) 2011-05-24
EP1891054A1 (fr) 2008-02-27
CN101248061B (zh) 2011-08-24
WO2006131632A1 (fr) 2006-12-14
FR2886642A1 (fr) 2006-12-08
RU2007149526A (ru) 2009-07-20
JP2008542435A (ja) 2008-11-27
IL187723A0 (en) 2008-08-07
CA2610665A1 (fr) 2006-12-14
US20080096944A1 (en) 2008-04-24
FR2886642B1 (fr) 2008-05-30
RU2401266C2 (ru) 2010-10-10
MX2007015426A (es) 2008-02-19
AU2006256678A1 (en) 2006-12-14
HK1123793A1 (en) 2009-06-26
AR054131A1 (es) 2007-06-06
UY29584A1 (es) 2007-01-31
BRPI0610933A2 (pt) 2010-08-03
KR20080024473A (ko) 2008-03-18
TW200716099A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
AU2006276205B2 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
KR102003570B1 (ko) 고순도 가도부트롤의 제조
TW420676B (en) Process for the preparation of a magnesium salt of a substituted sulphinyl heterocycle
JP6556293B2 (ja) 純粋なニロチニブ及びその塩の調製のための方法
WO2005080358A2 (en) Rosiglitazone phosphate and polymorphic forms
EP2448945B1 (en) Crystalline forms of prasugrel salts
KR102265637B1 (ko) 1,4,7,10-테트라아자시클로도데칸-1,4,7,10-테트라아세트산의 제조 방법
SK287424B6 (sk) Lítiové komplexy N-(1-hydroxymetyl-2,3-dihydroxypropyl)-1,4,7- triskarboxymetyl-1,4,7,10-tetraazacyklodekánu, ich výroba a použitie
CN101248061B (zh) 厄贝沙坦碱土金属盐水合物及其制备
KR20210057759A (ko) 설폰아미드 구조 키나아제 억제제의 신규한 염산염 형태
WO2014012849A1 (en) A new crystal form of cefoperazone sodium
KR102551433B1 (ko) 보르티옥세틴 hbr 알파-형태의 제조 방법
JP2002338578A (ja) β−ラクタム化合物の水和物結晶
EP3398946B1 (en) Salt of morpholine derivative and crystalline form thereof, as well as preparation method, pharmaceutical composition and use of the same
CZ2013943A3 (cs) Krystalické formy vemurafenibu
CN109641856B (zh) 缬沙坦二钠盐的晶型
CZ2012274A3 (cs) Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
HU231012B1 (hu) Lapatinib sók
EA043764B1 (ru) Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы
GB2421240A (en) Phosphoric acid salt of rosiglitazone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123793

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1123793

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110824

Termination date: 20150606

EXPY Termination of patent right or utility model